Biogen drops controversial Alzheimer's drug Aduhelm to focus on Leqembi, experimental treatments
Publishing timestamp: 2024-01-31 12:24:53
Summary
Biogen has announced that it will discontinue the sale and development of its Alzheimer's drug Aduhelm in order to focus on other treatments for the disease. The company will continue to roll out Leqembi, a newly approved Alzheimer's drug developed with Eisai, and work on experimental treatments. The decision is not related to safety or efficacy concerns, but rather a strategic shift in priorities.
Sentiment: MIXED
Keywords: health care industry, business, science, biotech and pharmaceuticals, biotechnology, biogen inc, eisai co ltd, business news, alzheimer's disease, pharmaceuticals,
Source: https://www.cnbc.com/2024/01/31/biogen-drops-alzheimers-drug-aduhelm-to-focus-on-leqembi-others.html